First AD

Second AD

FLAURA and FLAURA2: Key Efficacy and Safety Data

Video content above is prompted by the following:

Please comment on FLAURA2 PFS benefits in patients with extrathoracic metastases. How do these findings influence treatment choices for this patient population?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Unraveling The Key Questions in EGFR-Driven NSCLC Treatment 

OncLive Insights

Panelists discuss how FLAURA2's impressive progression-free survival (PFS) benefit with osimertinib plus chemotherapy was particularly pronounced in patients with extrathoracic metastases, suggesting this combination approach may be especially valuable for this higher-risk population, though careful consideration of individual patient factors and toxicity management remains important in treatment selection.

CNS Activity in EGFR mNSCLC